Seeking Alpha • Apr 08

AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

Summary AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029. ATAI is well-capitalized with $220.7M in cash, sufficient to fund operations into 2029 and progress multiple TRD and neuroplastogen programs. Read the full article on Seeking Alpha

분석 기사 • May 16

Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Seeking Alpha • Apr 21

Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating

Summary Initiate a Hold rating on Atai Life Sciences due to regulatory uncertainty and the need for robust, confirmatory Phase 2 and Phase 3 data. Atai's clinical pipeline includes promising treatments for mental health disorders, but regulatory pathways for psychedelic therapies remain unsettled, posing significant approval challenges. The market potential for Atai's therapies is substantial but crowded, with significant opportunities in treatment-resistant depression, social anxiety disorder, and cognitive impairment in schizophrenia. Atai's financial resources appear sufficient to fund key milestones into late 2026, but future funding needs and potential shareholder dilution are key risks. Read the full article on Seeking Alpha

Seeking Alpha • Feb 27

Atai: Following The Path That Spravato Laid And Moving Beyond It

Summary Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato. Upcoming milestones and clinical trials. Psychedelic industry sentiment; RFK Jr influence. Read the full article on Seeking Alpha

Seeking Alpha • Jan 29

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Summary Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results from the phase 2b study using BPL-003 for treatment-resistant depression expected in mid-2025. The global treatment-resistant depression treatment market is projected to reach $4.06 billion by 2030. Atai's diversified pipeline includes RL-007 for cognitive impairment associated with schizophrenia, VLS-01 for TRD, and EMP-01 for social anxiety disorder, with key data readouts in 2025. Read the full article on Seeking Alpha

Seeking Alpha • Sep 03

Psychedelic Stock Deep Dive: Atai Life Sciences

Summary After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move. Read the full article on Seeking Alpha

분석 기사 • Jul 15

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Seeking Alpha • May 27

ATAI: Enormous Potential Upside But No Clarity Yet

Summary Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase III data for COMP-360, are expected to impact the psychedelic drug industry. ATAI, an investment platform, offers cost control, diversification, and strategic investments, making it an attractive choice over COMPASS Pathways. Read the full article on Seeking Alpha

분석 기사 • Mar 02

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Seeking Alpha • Oct 12

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

A drug from atai Life Sciences (NASDAQ:ATAI) based on an active component found in the plant kratom led to pain-relieving effects in an early-stage trial. The candidate, KUR-101, is an oral form of deuterated mitragynine, the major active alkaloid found in kratom. It is under investigation for opioid use disorder. Results showed that KUR-101 was safe and well-tolerated with a dose-proportional pharmacokinetic profile. Additional results, including comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, is expected by the end of the year. Read why Seeking Alpha contributor Stephen Tobin is bullish on atai Life Sciences (ATAI).

Seeking Alpha • Oct 06

Atai Life Sciences: Decentralized Drug Discovery Platform

Summary ATAI is at a value inflection point, it has slimmed its drug discovery pipeline and promises proof of concept data within two years. ATAI has taken on debt to give it a cash runway through to 2025, by which time it must have generated compelling evidence for its drugs. I believe three drugs under development have a good chance of success and will have a strong competitive position if approved. Atai Life Sciences (ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them. It is a "company builder" I only know of two other companies with this model in the pharmaceutical industry BridgeBio (BBIO) and PureTech Health (PRTC). The recently appointed CFO of ATAI, Stephen Bardin, has moved to ATAI from BridgeBio. These companies have not done well of late. They are down 76% and 42%, respectively, with ATAI down 76% in the last 12 months. ATAI identifies promising mental health technologies or drugs and then acquires a stock interest, providing technical and financial support to hasten the time to market. ATAI companies are developing psychedelic and none-psychedelic compounds and technology for treating psychiatric disorders. ATAI current situation During the full year 2021 earnings call, ATAI talked about 13 drug development programs and four enabling technologies. In a recent press release, ATAI announced they had slimmed the drug development programs to 8 by focussing on the most promising programs that will generate meaningful data in the next two years. During the latest earnings call, we learned that ATAI had arranged a $175 million loan facility that brings total available cash to more than $300 million, extending its cash runway into 2025. However, by the end of 2025, the $300 million might have gone, and ATAI will likely have significant debt and most likely zero revenue. If an investment in ATAI is going to make money, then one of its eight drug programs must be a success. In this article, I will focus on the eight drug candidates under the ATAI umbrella, and a later article will look at the none drug products. The 8 ATAI drug programs hope to treat one of four mental health disorders. I will look at each disorder and evaluate the compounds being explored by ATAI, trying to judge their competitive situation. I will consider the evidence that they may be effective and safe and the potential market for the drug. None of the ATAI drugs will likely be approved within 3-5 years as all of their drugs are in phase I or II testing. However, all their candidates will release necessary proof of concept data within two years, and a good readout will lift the share price. ATAI was initially formed as an investment vehicle to invest in COMPASS Pathways (CMPS) and is a 24% shareholder in COMPASS. COMPASS Pathways is leading the way for psychedelic companies as it moves toward phase III testing. I previously wrote about COMPASS in-depth and will only consider it a competitor to ATAI when I assess the eight drug programs. Treatment-Resistant Depression Treatment Resistant Depression (TRD) has a significant unmet need; patients will have tried at least two previous treatments to be treatment resistive. ATAI has two drug candidates targeting this condition. COMPASS Pathways is about to take its Psilocybin-based compound to Phase 3 trial (we should get detail in mid-October) and has breakthrough therapy designation from the FDA, which should speed its path to approval. CMPS is leading the field for this condition and will likely be approved much earlier than any other compound. ATAI Candidate 1: PCN-101 PCN-101 is a patent-protected R-Ketamine compound. Ketamine is approved as a treatment for depression, and Numinus Wellness (NUMI) offers a wide range of Ketamine-assisted therapy in North America and Europe. The chemical structure of Ketamine is a mixture of two molecules, S-Ketamine and R-Ketamine. The FDA approved S-Ketamine for use with treatment-resistant depression in 2019; however, due to side effects, it must be administered in a clinic. The approval came with the following advisory. patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug. Because of the risk of sedation and dissociation, patients must be monitored by a health care provider for at least two hours after receiving their Spravato dose. ATAI believes that R-ketamine will be equally effective as S-Ketamine but without the side effects and could be approved for at-home use. This would be a significant advantage for the five or six million US adults that suffer from treatment-resistant depression. A search of available research suggests that R-Ketamine has greater potency and more prolonged lasting effects than S-Ketamine. ATAI Candidate 2: VLS-01 Derived from Ayahuasca, this hallucinogenic compound called N-Dimethyltryptamine ((DMT for short)) has a significant amount of study suggesting it is safe to use and an effective compound for altering mood. It has a very rapid onset but does require a clinic visit of about 2 hours, VLS-01 is being investigated for several other disorders. ATAI has recently dosed its first patient. I don't believe that the competitive situation for VLS-01 is as strong as PCN-101, as a psychedelic it requires clinical visits. Although research suggests it will be effective, it uses the same pharmacological mechanism as the other psychedelic drugs and may not offer any additional benefits. Other companies are also investigating TRD: Braxia Scientific (BRAX), have a phase II trial using Psilocybin to treat TRD and already have significant penetration of the general depression market through their KetaMD platform. GH Research has completed two phase I trials with GHoo1, proprietary and patent-protected 5-MeO-DMT-based compound with no severe side effects and more than 80% of patients reporting improved symptoms. 5-MeO-DMT is a naturally occurring psychedelic compound found in several plants in south America and at least one toad species. The value of PCN-101 is "at home use" it is the only drug currently in trial for this patient group that could potentially be administered at home. S-Ketamine, Psilocybin, and COMP360 require extensive clinic attendance. If it is successful in trials and ATAI can get it approved for at-home use it could be a huge seller. PCN-101 is currently in phase 2 testing. A readout from this study is expected in November 2022, and if positive, we could see a jump in share price and the start of a phase three trial. This is the first of the three compounds I think could be a success for ATAI. Anxiety Disorders Anxiety is a growing problem and is currently not well served pharmacologically. The market here could be huge; the US alone is thought to have more than 50 million people suffering the various forms of anxiety. The first line of drugs is usually SSRI (antidepressants), but these drugs are not well tolerated and are slow acting. Many patients fail to adhere to the dose, losing confidence in the drug, and as a result, they are considered somewhat ineffective. The second line of drugs is Benzodiazepines (like Xanax), these fast-acting and effective compounds come with significant risks of impaired cognition and sedation; they can be highly addictive. Outside of the US, a third treatment option exists. Etifoxine was developed in the 1960s as an alternative to drugs like valium. In 2000 French scientists discovered its dual action pharmacology which has led to the possibility of the drug being re-purposed as a cure to anxiety as it affects the GABA receptors in the brain. Etifoxine was approved many years ago in France, and more than 14 million subscriptions have been taken with zero addictions reported and a good safety standard generally. The drug was never introduced in the US or any other primary markets outside of France; it is already out of patent, so no business rationale exists for re-purposing it into other markets. ATAI Candidate 3: GRX-917 GRX-917 is a deuterated Etifoxine (change to the Hydrogen atoms that improves safety and effectiveness). It is a patent-covered formula currently in phase I testing by GABA Therapeutics. Early research suggests that GRX-917 will have the efficacy of Benzodiazepines without any side effects or risks of addiction. We know from the French experience that the drug is likely to be safe and effective. It is not a Psychadelic compound which may make the approval process more straightforward. Competition in this disorder is somewhat limited MindMed (MNMD) has a phase II trial using LSD (you can read my views on MindMed here). Incannex has a phase II study with Psilocybin, and Diamond Therapeutics have a Phase I with Psilocybin. GRX-917 appears to be the only non-psychedelic compound that may work in this area. A positive readout from the current trial (due next year) might result in a significant share price jump. Existing evidence for Etifoxine suggests that a positive readout is likely and that GRX-917 could be the blockbusting drug I am looking for and is the second compound I think could be a success. Cognitive Impairment Associated with Schizophrenia 80% of schizophrenia patients exhibit cognitive impairment ((CIAS)), and there is currently no approved treatment. The 24 million sufferers in the US cost medicare around $150 billion a year, and it is the 15th largest cause of disability. Recognify Life Science, ATAI controlled, is investigating the drug RL-007 and they have strong patents already approved. ATAI Candidate 4: RL-007 RL-007 (first developed and patented by Allergen now part of AbbVie in 2015 under the chemical formula (2R, 3S) -2-amino-3-hydroxy-3-pyridine-4-yl-1-pyrrolidine-1-yl-propane-1-one ((L)) - (+) - tartrate salt) is now exclusively licensed by Recognify. In December 2021, ATAI released the phase 2a data from 32 patients, showing significant improvement and supporting a more extensive trial. Two other drug companies Boehringer and Biogen have drugs in phase two trials for CIAS. It is just too early for me to predict the likely success of RL-007, as a relatively new compound, little research evidence exists, and it is impossible to know how it will stack up against the two competitors which are at the same stage of development. Substance Abuse The FDA has stated that: there currently are no products with demonstrated or purported reduced abuse liability on the market. As such, it represents a huge unmet need, and any successful drug will have a significant market.

Seeking Alpha • Aug 15

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

ATAI Life Sciences press release (NASDAQ:ATAI): Q2 GAAP EPS of -$0.24 misses by $0.01. Cash, cash equivalents and short-term investments totaled $312.5 million as of June 30, 2022, compared to $362.3 million as of December 31, 2021.

분석 기사 • Aug 07

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jul 07

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

ATAI is backed by Peter Thiel. Its decentralized business model is pretty unique. I will wait for more data before I take a call on this very interesting company. Atai Life Sciences N.V. (ATAI) is a German-headquartered developer of medicines for mental health disorders. Atai is backed by billionaire investor Peter Thiel. It takes up compounds already known to be safe and effective in humans, as well as psychedelic compounds with known activity in humans, and then forms small affiliate companies around these drug candidates (it also forms affiliates to support some of its platforms, like intranasal delivery). The concept is novel, however, this is still at an early stage. The company's drug candidate pipeline looks like this: ATAI Pipeline (atai website) Lead program is PCN-101 / R-ketamine targeting Treatment Resistant Depression or TRD. Second program is RL-007 targeting Cognitive Impairment Associated With Schizophrenia. These two programs are currently running phase 2 trials. The company claims 17 active programs, four of which are "enabling technologies" focused on compound classes with prior evidence in humans, and 13 drug discovery programs in various stages. Atai operates in a decentralized manner. It has an affiliate of 18 small companies - some of these are listed in the diagram above. These companies, although decentralized, have access to shared resources, and are allocated capital accordingly. They have operational autonomy to develop compounds, with core guidance from the co-founders. I don't think I have seen exactly this model anywhere before. Lead indication is treatment-resistant depression, which is diagnosed after two failed doses of antidepressants. This amounts to a third of all depression patients. The economic burden of depression is huge, running into hundreds of billions of dollars. There are over 300 million people worldwide diagnosed with depression. There are very few treatment options. Only 6 drugs have been approved in the last 5 years. Atai has 2 clinical stage assets targeting TRD, and multiple preclinical ones. The most advanced asset is COMP360, which is being jointly developed with Compass Pathways (CMPS). Atai has a 22.5% stake. This asset toplined a phase 2b trial last year. In that study, COMP360 demonstrated efficacy in reducing depressive symptom severity with rapid and durable response. In November, the 25mg cohort from this study attained the primary endpoint. In a scale to measure the disease called MADRS, those who received 25mg showed a -6.6 difference vs. the comparator group at week 3 (p<0.001). COMP360 is an oral reformulation of Psilocybin, a psychoactive ingredient found in some species of "magic mushrooms." PCN-101, in which Atai has a 58.9% stake, completed a phase 1 study which showed safety and tolerability of R-ketamine at doses of up to 150mg. They now have a proof of concept phase 2 trial ongoing. Earlier, a phase 1 trial showed a distinct superiority of R-ketamine over S-Ketamine, suggesting that the former can be used at home. It was observed that the onset of dissociative and psychotomimetic effects occurred at fourfold higher doses than the equimolar doses of S-ketamine. The equivalent CADSS scores are from 12 to 15, scores that were observed in the 30mg and 60mg doses of PCN-101. The company has thus decided to use these two doses in the phase 2 trial. These doses may potentially be given at home. RL-007 has safety and tolerability data. An ongoing Phase 2 trial showed pro-cognitive potential of RL-007 in 180 patients with diabetic peripheral neuropathic pain. Earlier data also showed improvement in learning and memory. One good thing to Atai's approach of using previously-tested molecules is that they can use some of that old data in their trials. However, this may lead to lower competitive hurdles. Atai owns 51.9% of this asset. The company needs to work very hard to protect its intellectual property. The other assets lack any data at this time. Financials

Seeking Alpha • Jun 30

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Kures Therapeutics, an atai Life Sciences (NASDAQ:ATAI) appoints of Chad E. Beyer, Ph.D., MBA, as CEO of Kures succeeding Dr. Srinivas Rao, effective July 1, 2022. Dr. Srinivas Rao will continue to support and advise Kures’ programs from his role at atai Life Sciences. Most recently Dr. Beyer served as senior VP of Research and Development at Promentis Pharmaceuticals.

Seeking Alpha • Jun 02

Atai Life Sciences N.V.: A First Take

Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company’s approach of identifying (in many instances psychedelic) compounds that have been tested in previous human trials marginally de-risks its programs. With the market placing a valuation of ~$210 million on ten of its 11 programs – many with blockbuster potential – the recent insider buying merited further investigation. A full investment analysis follows in the paragraphs below.

Seeking Alpha • May 27

Atai Life Sciences And The Future Of Psychedelics For Mental Health

ATAI has a large portfolio of drugs, mainly psychedelics, that can be used to treat mental health conditions when other options have failed. There is ample room for new drug developments in this space, given that R&D for new drug developments has been declining. Success depends on legal changes, so it seems too early to initiate a position at the moment.

분석 기사 • Apr 22

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

스노우플레이크 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 건전성	6/6
배당	0/6

과거 주가
현재 주가	US$4.09
52주 최고가	US$6.75
52주 최저가	US$1.89
베타	1.6
1개월 변동	-16.53%
3개월 변동	7.07%
1년 변동	114.14%
3년 변동	125.97%
5년 변동	n/a
IPO 이후 변동	-78.97%

	ATAI	US Pharmaceuticals	US 시장
7D	-3.5%	-0.1%	-0.3%
1Y	114.1%	38.7%	26.7%

ATAI volatility
ATAI Average Weekly Movement	11.1%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

ATAI 기초 통계
시가총액	US$1.45b
순이익 (TTM)	-US$663.40m
매출 (TTM)	US$3.49m

ATAI 손익계산서 (TTM)
매출	US$3.49m
매출원가	US$47.61m
총이익	-US$44.12m
기타 비용	US$619.28m
순이익	-US$663.40m

주당순이익(EPS)	-1.81
총이익률	-1,264.91%
순이익률	-19,019.44%
부채/자본 비율	0%

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/20 14:02
종가	2026/05/20 00:00
수익	2026/03/31
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
David Bouchey	Aegis Capital Corporation
Harry Gillis	Berenberg
Samuel England	Berenberg

AtaiBeckley (ATAI) 주식 개요

강점

위험 분석

AtaiBeckley Inc. 경쟁사

Lexicon Pharmaceuticals

Tarsus Pharmaceuticals

Nuvation Bio

Zevra Therapeutics

가격 이력 및 성과

최근 뉴스 및 업데이트

Consensus revenue estimates increase by 104%

ATAI: Advancing the Short-Acting Psychedelic Pivot via VLS-01 and the Clinical Maturation of Rapid-Acting Mental Health Therapeutics

AtaiBeckley Sees Strong Analyst Support After Positive Phase 2a Results for Oral Social Anxiety Drug

AtaiBeckley Inc. Announces Additional Phase 2A Results for EMP-01 Oral R-M Showing Large and Consistent Improvements in Social Anxiety Disorder

AtaiBeckley Inc., Annual General Meeting, Jun 04, 2026

AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

Recent updates

Consensus revenue estimates increase by 104%

ATAI: Advancing the Short-Acting Psychedelic Pivot via VLS-01 and the Clinical Maturation of Rapid-Acting Mental Health Therapeutics

AtaiBeckley Sees Strong Analyst Support After Positive Phase 2a Results for Oral Social Anxiety Drug

AtaiBeckley Inc. Announces Additional Phase 2A Results for EMP-01 Oral R-M Showing Large and Consistent Improvements in Social Anxiety Disorder

AtaiBeckley Inc., Annual General Meeting, Jun 04, 2026

AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

AtaiBeckley Inc. Shows Rapid And Durable Antidepressant Response With BPL-003 In Treatment-Resistant Depression Patients

AtaiBeckley Inc Demonstrates Rapid And Durable Antidepressant Effects In Treatment-Resistant Depression

AtaiBeckley Inc Announces Successful End-Of-Phase 2 Meeting For BPL-003 In Treatment-Resistant Depression

AtaiBeckley Inc. Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

AtaiBeckley Inc. Announces Executive Changes, Effective March 9, 2026

AtaiBeckley Inc. Announces Resignation of Cosmo Feilding-Mellen from Board of Directors, Effective January 6, 2026

AtaiBeckley Completes Redomiciliation to the United States

Atai Beckley N.V. Files Form 15

Atai Beckley N.V. Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003

AtaiBeckleyAnnounces Board Changes

Atai Life Sciences N.V. and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003

atai Life Sciences and Beckley Psytech Limited Report Positive Phase 2a Data Demonstrating Improved Outcomes with A Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences Awards Grant from the National Institutes of Health

Atai Life Sciences N.V. announced that it expects to receive $50 million in funding

Atai Life Sciences N.V. (NasdaqGM:ATAI) entered into a share purchase agreement to acquire an additional unknown minority stake in Beckley Psytech Limited from shareholders for approximately €210 million.

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating

Atai Life Sciences N.V., Annual General Meeting, May 15, 2025

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

atai Life Sciences Announces Completion of Enrollment in Phase 2B Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

Atai: Following The Path That Spravato Laid And Moving Beyond It

Atai Life Sciences N.V. has filed a Follow-on Equity Offering in the amount of $55 million.

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

Atai Life Sciences N.V. Announces Resignation of Michael Auerbach as Member of the Supervisory Board of Directors and Supervisory Board’s Compensation Committee

Srinivas Rao Assumes the Role of Sole CEO of Atai Life Sciences N.V

Psychedelic Stock Deep Dive: Atai Life Sciences

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Bccal Film DMT)

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

Atai Life Sciences Announces Update on Beckley Psytech’S Phase 1/2A Trial of Ele-101 (Iv Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2A

ATAI: Enormous Potential Upside But No Clarity Yet

Atai Life Sciences N.V. Announces Board and Supervisory Board Changes

Co-Founder recently sold US$291k worth of stock

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2023)

Atai Life Sciences N.V. Announces CEO Changes

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Atai Life Sciences N.V., Annual General Meeting, May 17, 2024

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Co-Founder & Chief Scientific Officer recently sold US$114k worth of stock

Price target decreased by 19% to US$11.80

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Price target increased by 18% to US$14.50

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences Announces Management Changes

Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.22 loss in 3Q 2022)

Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc.

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Co-Founder & CEO recently bought US$58k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 48%, EPS upgraded

atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine)